This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tai, P. T. H. Articles by Gilchrist, J. Search for Related Content PubMed PubMed Citation Articles by Tai, P. T. H. Articles by Gilchrist, J. Social Bookmarking                            What's this?

Chemotherapy in Neuroendocrine/Merkel Cell Carcinoma of the Skin: Case Series and Review of 204 Cases

From the London Regional Cancer Center, London, Ontario, Canada.

Address reprint requests to Patricia T.H. Tai, MD, Allan Blair Cancer Center, 4101 Dewdney Ave, Regina, SK S4T 7T1, Canada; email ptai{at}scf.sk.ca

ABSTRACT

PURPOSE: To study the use of chemotherapy for Merkel cell carcinoma (MCC) of the skin.

PATIENTS AND METHODS: Twenty-five cases of MCC were treated at the London Regional Cancer Center between 1987 and 1997. Thirteen cases treated with chemotherapy were reviewed with 191 cases from the literature.

RESULTS: At presentation, 24 patients had localized skin lesions (stage I) and one had locoregional involvement (stage II). Among the nine cases with recurrent nodal disease, six had chemotherapy as a component of salvage treatment. They were all free of disease at a median of 19 months (range, 12 to 37 months). In contrast, two patients who had salvage radiotherapy alone died of disease. Overall survival (OS) and disease-free survival (DFS) were 59% and 43%, respectively, at two years. Median OS and DFS were 29 months (range, 1 to 133 months) and 9 months (range, 1 to 133 months), respectively. Nodal disease developed in 12 (50%) of 24 patients with stage I disease, and distant metastases developed in six (25%) of 24. Including those from the literature, there were 204 cases treated with chemotherapy. Cyclophosphamide/doxorubicin (or epirubicin)/vincristine combination ± prednisone was the most commonly used chemotherapy regimen (47 cases), with an overall response rate of 75.7% (35.1% complete, 35.1% partial, and 5.4% minor responses). Etoposide/cisplatin (or carboplatin) was the next most commonly used regimen (27 cases), with an overall response rate of 60% (36% complete and 24% partial responses). The difference in response rate was not statistically significant (P = .19). Among the 204 cases, there were seven (3.4%) toxic deaths.

CONCLUSION: Chemoradiation for locally recurrent or advanced disease may be an option for patients with a good performance status.

NOTES

Presented in part at the Royal College of Physicians and Surgeons of Canada, Sixty-Seventh Annual Scientific Meeting held jointly with the Canadian Association of Radiation Oncologists, Toronto, Canada, September 24-27, 1998.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. H. Ruan and M. Reeves A Merkel Cell Carcinoma Treatment Algorithm Arch Surg, June 1, 2009; 144(6): 582 - 585. [Abstract] [Full Text] [PDF]

				R. E. Warner, M. J. Quinn, G. Hruby, R. A. Scolyer, R. F. Uren, and J. F. Thompson Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy Ann. Surg. Oncol., September 1, 2008; 15(9): 2509 - 2518. [Abstract] [Full Text] [PDF]

				J. A. Fiorillo Merkel Cell Carcinoma Metastatic to the Heart J. Clin. Oncol., July 20, 2008; 26(21): 3643 - 3644. [Full Text] [PDF]

				P. M. Busse, J. R. Clark, V. V. Muse, and V. Liu Case 19-2008 -- A 63-Year-Old HIV-Positive Man with Cutaneous Merkel-Cell Carcinoma N. Engl. J. Med., June 19, 2008; 358(25): 2717 - 2723. [Full Text] [PDF]

				S Altintas, N Blockx, M. Huizing, J Van den Brande, L Hoekx, J. Bogers, E Van Marck, and J. Vermorken Small-cell carcinoma of the penile urethra: a case report and a short review of the literature Ann. Onc., April 1, 2007; 18(4): 801 - 804. [Full Text] [PDF]

				D Pectasides, M Pectasides, and T Economopoulos Merkel cell cancer of the skin Ann. Onc., October 1, 2006; 17(10): 1489 - 1495. [Abstract] [Full Text] [PDF]

				R. A. Howard, G. M. Dores, R. E. Curtis, W. F. Anderson, and L. B. Travis Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1545 - 1549. [Abstract] [Full Text] [PDF]

				S. G. Gupta, L. C. Wang, P. F. Penas, M. Gellenthin, S. J. Lee, and P. Nghiem Sentinel Lymph Node Biopsy for Evaluation and Treatment of Patients With Merkel Cell Carcinoma: The Dana-Farber Experience and Meta-analysis of the Literature. Arch Dermatol, June 1, 2006; 142(6): 685 - 690. [Abstract] [Full Text] [PDF]

				M. K. Tummala, P. F. Hausner, W. P. McGuire, T. Gipson, and A. Berkman CASE 1. Testis: A Sanctuary Site in Merkel Cell Carcinoma J. Clin. Oncol., February 20, 2006; 24(6): 1008 - 1009. [Full Text] [PDF]

				P. J. Allen, W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, and D. G. Coit Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution J. Clin. Oncol., April 1, 2005; 23(10): 2300 - 2309. [Abstract] [Full Text] [PDF]

				M.R.M. Jongbloed, B.L.J. Kanen, M. Visser, H. Niessen, M.J. Flens, and R.J.L.F. Loffeld Unusual Sites of Metastatic Involvement: CASE 2. Intracardiac Metastasis From a Merkel Cell Carcinoma J. Clin. Oncol., March 15, 2004; 22(6): 1153 - 1156. [Full Text] [PDF]

				W. Goessling, P. H. McKee, and R. J. Mayer Merkel Cell Carcinoma J. Clin. Oncol., January 15, 2002; 20(2): 588 - 598. [Full Text] [PDF]

				H. Medina-Franco, M. M. Urist, J. Fiveash, M. J. Heslin, K. I. Bland, and S. W. Beenken Multimodality Treatment of Merkel Cell Carcinoma: Case Series and Literature Review of 1024 Cases Ann. Surg. Oncol., April 1, 2001; 8(3): 204 - 208. [Abstract] [Full Text] [PDF]